AR035775A1 - Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen - Google Patents
Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR035775A1 AR035775A1 ARP010106092A ARP010106092A AR035775A1 AR 035775 A1 AR035775 A1 AR 035775A1 AR P010106092 A ARP010106092 A AR P010106092A AR P010106092 A ARP010106092 A AR P010106092A AR 035775 A1 AR035775 A1 AR 035775A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecular weight
- low molecular
- substituted
- halogen
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 24
- 125000000623 heterocyclic group Chemical group 0.000 abstract 22
- 125000000217 alkyl group Chemical group 0.000 abstract 19
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 15
- 229910052736 halogen Inorganic materials 0.000 abstract 15
- 150000002367 halogens Chemical class 0.000 abstract 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 12
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000004414 alkyl thio group Chemical group 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 9
- 125000003282 alkyl amino group Chemical group 0.000 abstract 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 9
- 125000005100 aryl amino carbonyl group Chemical group 0.000 abstract 9
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 9
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 8
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 7
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 7
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 abstract 7
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 7
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- -1 methylenedioxy Chemical group 0.000 abstract 3
- 229910052757 nitrogen Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- BBNGVMNBBLPZIR-UHFFFAOYSA-N 4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)N=CNC2=C1 BBNGVMNBBLPZIR-UHFFFAOYSA-N 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25933701P | 2001-01-02 | 2001-01-02 | |
| US32526701P | 2001-09-27 | 2001-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035775A1 true AR035775A1 (es) | 2004-07-14 |
Family
ID=26947245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010106092A AR035775A1 (es) | 2001-01-02 | 2001-12-28 | Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1363899B1 (enExample) |
| JP (1) | JP4031363B2 (enExample) |
| KR (1) | KR100554813B1 (enExample) |
| CN (1) | CN1237060C (enExample) |
| AR (1) | AR035775A1 (enExample) |
| AT (1) | ATE295362T1 (enExample) |
| BR (1) | BR0116662A (enExample) |
| CA (1) | CA2432578C (enExample) |
| DE (1) | DE60110844T2 (enExample) |
| ES (1) | ES2241891T3 (enExample) |
| MX (1) | MXPA03005854A (enExample) |
| PA (1) | PA8536001A1 (enExample) |
| PE (1) | PE20020735A1 (enExample) |
| UY (1) | UY27109A1 (enExample) |
| WO (1) | WO2002053558A1 (enExample) |
| ZA (1) | ZA200305038B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| CA2530312A1 (en) | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | Arylamine-substituted quinazolinone compounds |
| MXPA06000185A (es) * | 2003-07-02 | 2006-04-11 | Hoffmann La Roche | Derivados de quinazolinas 5-sustituidas. |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
| FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| US7745451B2 (en) | 2005-05-04 | 2010-06-29 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions |
| JP2009507032A (ja) | 2005-09-02 | 2009-02-19 | アボット・ラボラトリーズ | 新規なイミダゾ系複素環 |
| KR101232425B1 (ko) * | 2005-11-24 | 2013-02-12 | 깃세이 야쿠힌 고교 가부시키가이샤 | 요관결석증 치료용 의약 |
| US8653091B2 (en) | 2007-04-02 | 2014-02-18 | Evotec Ag | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof |
| CN101677569B (zh) | 2007-04-17 | 2014-01-22 | 伊沃泰克股份公司 | 2-氰基苯基稠合杂环化合物及其组合物和用途 |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| CN101417999A (zh) * | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| JO3156B1 (ar) * | 2009-07-09 | 2017-09-20 | Novartis Ag | ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا |
| WO2015018797A2 (en) * | 2013-08-05 | 2015-02-12 | Haplogen Gmbh | Antiviral compounds |
| GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2754430T3 (es) * | 2013-12-20 | 2020-04-17 | Esteve Pharmaceuticals Sa | Derivados de imidazolilo fusionados, su preparación y uso como medicamentos |
| MX382339B (es) | 2016-05-18 | 2025-03-13 | Mirati Therapeutics Inc | Inhibidores g12c de kras. |
| CN107434786B (zh) * | 2016-05-27 | 2025-11-18 | 广东东阳光药业股份有限公司 | 苯并咪唑化合物及其制备方法 |
| EP3615030A1 (en) | 2017-04-24 | 2020-03-04 | Novartis AG | Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| CN112955137B (zh) | 2018-09-10 | 2025-05-13 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| LT3849537T (lt) | 2018-09-10 | 2025-02-10 | Mirati Therapeutics, Inc. | Kompleksinės terapijos |
| SG11202102357RA (en) | 2018-12-05 | 2021-04-29 | Mirati Therapeutics Inc | Combination therapies |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| AU2020232616A1 (en) * | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
| CN110950886A (zh) * | 2019-12-13 | 2020-04-03 | 苏州莱克施德药业有限公司 | 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法 |
| CN115135315B (zh) | 2019-12-20 | 2024-11-26 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| CA3190944A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| US11999753B2 (en) | 2020-12-16 | 2024-06-04 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-KRas inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
| DE2757925A1 (de) * | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| GB9526546D0 (en) * | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| AU3555200A (en) * | 1999-03-17 | 2000-10-04 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
-
2001
- 2001-12-17 MX MXPA03005854A patent/MXPA03005854A/es active IP Right Grant
- 2001-12-17 CN CNB018217133A patent/CN1237060C/zh not_active Expired - Fee Related
- 2001-12-17 KR KR1020037008921A patent/KR100554813B1/ko not_active Expired - Fee Related
- 2001-12-17 AT AT01985417T patent/ATE295362T1/de not_active IP Right Cessation
- 2001-12-17 WO PCT/EP2001/014885 patent/WO2002053558A1/en not_active Ceased
- 2001-12-17 BR BR0116662-0A patent/BR0116662A/pt not_active IP Right Cessation
- 2001-12-17 ES ES01985417T patent/ES2241891T3/es not_active Expired - Lifetime
- 2001-12-17 DE DE60110844T patent/DE60110844T2/de not_active Expired - Fee Related
- 2001-12-17 JP JP2002554677A patent/JP4031363B2/ja not_active Expired - Fee Related
- 2001-12-17 EP EP01985417A patent/EP1363899B1/en not_active Expired - Lifetime
- 2001-12-17 CA CA002432578A patent/CA2432578C/en not_active Expired - Fee Related
- 2001-12-27 PE PE2001001308A patent/PE20020735A1/es not_active Application Discontinuation
- 2001-12-27 PA PA20018536001A patent/PA8536001A1/es unknown
- 2001-12-28 AR ARP010106092A patent/AR035775A1/es unknown
- 2001-12-28 UY UY27109A patent/UY27109A1/es not_active Application Discontinuation
-
2003
- 2003-06-28 ZA ZA200305038A patent/ZA200305038B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY27109A1 (es) | 2002-07-31 |
| PA8536001A1 (es) | 2002-08-29 |
| CN1237060C (zh) | 2006-01-18 |
| JP4031363B2 (ja) | 2008-01-09 |
| JP2004519454A (ja) | 2004-07-02 |
| CN1484640A (zh) | 2004-03-24 |
| BR0116662A (pt) | 2003-09-23 |
| PE20020735A1 (es) | 2002-08-21 |
| KR20030063490A (ko) | 2003-07-28 |
| ATE295362T1 (de) | 2005-05-15 |
| CA2432578C (en) | 2008-04-01 |
| WO2002053558A1 (en) | 2002-07-11 |
| KR100554813B1 (ko) | 2006-02-22 |
| ES2241891T3 (es) | 2005-11-01 |
| EP1363899B1 (en) | 2005-05-11 |
| CA2432578A1 (en) | 2002-07-11 |
| MXPA03005854A (es) | 2003-09-10 |
| DE60110844T2 (de) | 2006-01-12 |
| ZA200305038B (en) | 2004-09-27 |
| EP1363899A1 (en) | 2003-11-26 |
| DE60110844D1 (de) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035775A1 (es) | Compuestos derivados de quinazolin-4-ona y benzo[1,2,4]tiadiazina-1,1-dióxido, su uso, un proceso para su obtencion y composiciones farmaceuticas que los contienen | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
| CL2004000174A1 (es) | Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer. | |
| EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| EA200300792A1 (ru) | Хиназолины в качестве ингибиторов ммр-13 | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| EA200300333A1 (ru) | Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
| AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
| AR031556A1 (es) | Derivados de 3-(diarilmetilen)-8-azabiciclo[3.2.1] octano y composiciones farmaceuticas que los comprenden | |
| UY25804A1 (es) | Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3 | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| MXPA05007496A (es) | Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes. | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| DE60014394D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| AR032475A1 (es) | Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende | |
| DE69018678D1 (de) | Trizyklische Lactamderivate und pharmazeutische Zusammensetzungen, die sie enthalten. | |
| EA200501148A1 (ru) | Пиридилоксиметильные и бензизоксазольные азабициклические производные | |
| AR009363A1 (es) | Compuestos 3-mercaptoacetilamino-1,5-sustituido--oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz, composicion farmaceutica y usos para la fabricacion de medicamentos para el tratamiento de enfermedades que responden a la inhibicion de metaloproteinasas de la matriz | |
| EA200300915A1 (ru) | Производные изоксазолина в качестве антидепрессантов | |
| RU2007125660A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |